switching to retatrutide from tirzepatide vs. Retatrutide: Key Differences Explained Why I Switched From Tirzepatide

Ozyazgan S, Kutluata N, Afsar S, Ozdas SB, Akkan AG: Effect of glucagon-like peptide-1(736) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats

The use of alcohol is connected to the progression of the disease [2]

Clinical reality: Mounjaro is often attractive because it appears simpler than daily medication

The drugs are generally well-tolerated, however, infrequent and transient, dose-related side effects may occur

The advent of glucagon-like peptide-1 receptor agonists (GLP-1RA) has transformed diabetes care, not only through improvements in HbA1c and body weight, but by demonstrating a consistent reduction in major adverse cardiovascular events (MACE)

In the SURMOUNT-1 trial, tirzepatide produced dose-dependent weight reductions, with average losses approaching or exceeding ~20% at higher doses in adults with obesity who did not have diabetes, numbers that markedly exceed historical pharmacotherapy benchmarks